Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.
|Articles|April 11, 2023
What Can Pharma Do for Patients Post IRA?
Kevin Hagan, president and CEO of the PAN Foundation, discusses how pharma can help Medicare patients post-IRA reform.
Advertisement
Kevin Hagan, president and CEO of the PAN Foundation, discusses how pharma can help Medicare patients post-IRA reform. Hagan notes there is a continuing need to have copay assistance because Medicare patients still face a $2K out of pocket cost, which is still a challenge for many of them.
Visit the PAN Foundation's "
Advertisement
Related to this article
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Five major pharma stories in one day — Novo's rebrand and AI bets, Bayer's 30-year CKD first, GSK's T-cell engager, and Sanofi's portfolio exit.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance, touches on what he sees as the most realistic path to making MFN pricing permanent.
Joe Cunningham argues that the most-favored-nation drug pricing agreements carry no legislative weight and discusses what the program actually locks in.
How the shifting tides in information consumption are resetting expectations for pharma in providing and delivering health education.
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz
2
The Battle to Own the GLP-1 Patient Journey
3
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
4
FDA Approves Kerendia for Adults with Chronic Kidney Disease and Type 1 Diabetes
5